EMA accepts Dynavax's MAA for Heplisav
This article was originally published in Scrip
The European Medicines Agency has accepted the marketing authorisation application (MAA) for Dynavax Technologies' hepatitis B vaccine, Heplisav, an immunostimulatory sequence targeting toll-like receptor 9 combined with hepatitis B surface antigen.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.